Shares of Jazz Pharmaceuticals (JAZZ) have gained 15.4% over the past four weeks to close the last trading session at $143.53, but there could still be a solid upside left in the stock if short-term ...

Fintel reports that on February 26, 2025, Cantor Fitzgerald downgraded their outlook for Jazz Pharmaceuticals (NasdaqGS:JAZZ) ...

Piper Sandler reaffirmed their overweight rating on shares of Jazz Pharmaceuticals (NASDAQ:JAZZ – Free Report) in a report ...

Jazz Pharmaceuticals ended 2024 on a strong note, beating analyst estimates. I continue to see Jazz stock as a valuation ...

Merely a minute into his prepared remarks during Jazz Pharmaceuticals’ fourth-quarter earnings call, CEO Bruce Cozadd brought ...

Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) beat Wall Street’s revenue expectations in Q4 CY2024, with sales up 7.5% ...

Barclays analyst Balaji Prasad raised the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $200 from $190 and keeps an Overweight rating ...

Jazz Pharmaceuticals PLC (JAZZ) achieves record-breaking revenue in 2024, outlines strategic growth initiatives for 2025 ...

Cantor Fitzgerald cut shares of Jazz Pharmaceuticals (NASDAQ:JAZZ – Free Report) from an overweight rating to a neutral rating in a report published on Wednesday, Marketbeat Ratings reports.

Truist Financial analyst Joon Lee maintained a Buy rating on Jazz Pharmaceuticals (JAZZ – Research Report) today. The company’s shares closed ...

JAZZ PHARMACEUTICALS ($JAZZ) posted quarterly earnings results on Tuesday, February 25th. The company reported earnings of $6.60 per share, beating estimates of $5.93 ...

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the full year and fourth quarter of 2024 and ...